dc.contributor.author |
Grau Cerrato, Santiago |
dc.contributor.author |
Echeverría Esnal, Daniel |
dc.contributor.author |
Gómez-Zorrilla, Silvia |
dc.contributor.author |
Navarrete Rouco, Maria Eugenia |
dc.contributor.author |
Masclans Enviz, Joan Ramon |
dc.contributor.author |
Espona, Mercè |
dc.contributor.author |
Gracia Arnillas, María Pilar |
dc.contributor.author |
Duran Jordà, Xavier, 1974- |
dc.contributor.author |
Comas Serrano, Mercè |
dc.contributor.author |
Horcajada Gallego, Juan Pablo |
dc.contributor.author |
Ferrández, Olivia |
dc.date.accessioned |
2021-06-25T07:24:04Z |
dc.date.available |
2021-06-25T07:24:04Z |
dc.date.issued |
2021 |
dc.identifier.citation |
Grau S, Echeverria-Esnal D, Gómez-Zorrilla S, Navarrete-Rouco ME, Masclans JR, Espona M, Gracia-Arnillas MP, Duran X, Comas M, Horcajada JP, Ferrández O. Evolution of antimicrobial consumption during the first wave of COVID-19 pandemic. Antibiotics (Basel). 2021;10(2):132. DOI: 10.3390/antibiotics10020132 |
dc.identifier.issn |
2079-6382 |
dc.identifier.uri |
http://hdl.handle.net/10230/47975 |
dc.description.abstract |
Background: The first wave of COVID-19 pandemic may have significantly impacted antimicrobial consumption in hospitals. The objective of this study was to assess the evolution of antimicrobial consumption during this period. Methods: A retrospective quasi-experimental before-after study was conducted in a Spanish tertiary care hospital. The study compared two periods: pre-pandemic, from January 2018 to February 2020, and during the COVID-19 pandemic from March to June 2020. Antimicrobial consumption was analyzed monthly as defined daily doses (DDD)/100 bed-days and overall hospital and ICU consumption were evaluated. Results: An increase in the hospital consumption was noticed. Although only ceftaroline achieved statistical significance (p = 0.014), a rise was observed in most of the studied antimicrobials. A clear temporal pattern was detected. While an increase in ceftriaxone and azithromycin was observed during March, an increment in the consumption of daptomycin, carbapenems, linezolid, ceftaroline, novel cephalosporin/β-lactamase inhibitors or triazoles during April-May was noticed. In the ICU, these findings were more evident, namely ceftriaxone (p = 0.029), carbapenems (p = 0.002), daptomycin (p = 0.002), azithromycin (p = 0.030), and linezolid (p = 0.011) but followed a similar temporal pattern. Conclusion: An increase in the antimicrobial consumption during the first wave of COVID-19 pandemic was noticed, especially in the ICU. Availability of updated protocols and antimicrobial stewardship programs are essential to optimize these outcomes. |
dc.format.mimetype |
application/pdf |
dc.language.iso |
eng |
dc.publisher |
MDPI |
dc.relation.ispartof |
Antibiotics (Basel). 2021;10(2):132 |
dc.rights |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
dc.rights.uri |
http://creativecommons.org/licenses/by/4.0/ |
dc.title |
Evolution of antimicrobial consumption during the first wave of COVID-19 pandemic |
dc.type |
info:eu-repo/semantics/article |
dc.identifier.doi |
http://dx.doi.org/10.3390/antibiotics10020132 |
dc.subject.keyword |
COVID-19 |
dc.subject.keyword |
Antibiotic consumption |
dc.subject.keyword |
Antimicrobial resistance |
dc.subject.keyword |
Antimicrobial stewardship |
dc.subject.keyword |
Defined daily doses (DDD) |
dc.rights.accessRights |
info:eu-repo/semantics/openAccess |
dc.type.version |
info:eu-repo/semantics/publishedVersion |